Stay updated on Durvalumab in Resectable Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Durvalumab in Resectable Lung Cancer Clinical Trial page.

Latest updates to the Durvalumab in Resectable Lung Cancer Clinical Trial page
- Check6 days agoChange DetectedThe Record History for NCT03800134 shows many version updates, with recurring changes to Study Status, Contacts/Locations, and IPDSharing, reflecting ongoing adjustments to trial status and participating sites. These updates affect current participation information and how to contact researchers.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check35 days agoChange Detected- Added a government operations notice and operating details, plus a new v3.2.0 revision. - Removed the previous v3.1.0 revision.SummaryDifference9%

- Check42 days agoChange DetectedUpdated the page revision from v3.0.2 to v3.1.0, indicating a new software release or document update. No changes to core content, pricing, or stock are evident.SummaryDifference0.2%

- Check57 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2; a 'Back to Top' link was removed as a minor UI change.SummaryDifference0.5%

- Check64 days agoChange DetectedThe web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.5%

- Check71 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location details, while removing specific location terms and listed countries. This indicates a shift towards a more streamlined presentation of study information.SummaryDifference54%

Stay in the know with updates to Durvalumab in Resectable Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab in Resectable Lung Cancer Clinical Trial page.